weight loss

Health tech startup Signos raised $20 million, deepening its partnership with Dexcom and entering the GLP-1 weight loss market. The investment will expand Signos’ AI capabilities for personalized metabolic health guidance, leveraging Dexcom’s glucose monitoring. Their system, FDA-cleared in 2025, offers actionable insights from lifestyle data to promote sustainable healthy habits and weight management, complementing GLP-1 treatments or serving as a standalone program.

Amazon is entering the weight-loss market with a new GLP-1 medication program via Amazon One Medical and Amazon Pharmacy. This initiative offers integrated virtual/in-person care, transparent pricing, and aims for same-day delivery in thousands of cities by 2026. Amazon’s move leverages its logistics and e-commerce expertise to disrupt chronic condition management and increase patient adherence.

A Chinese woman’s reported 3.6-pound weight loss after a two-hour karaoke session has sparked online interest in singing as a weight-loss method. Her fitness tracker indicated a 350-calorie burn. Experts suggest singing can be a form of aerobic exercise, elevating heart rate and strengthening lung function. However, they advise against relying solely on karaoke for weight loss, emphasizing that while it offers cardiovascular benefits, traditional exercises are more effective. The enjoyment factor of singing may contribute to consistency and potentially boost metabolism.

A 22-year-old woman in Chongqing, China, lost nearly ten pounds in six days by strategically choosing stair-climbing food delivery orders. This method, lauded online for its effectiveness, combines income generation with weight loss. Experts note stair climbing can be HIIT, improving cardiovascular health and muscle mass. However, due to knee joint stress, it’s not for everyone. Consulting a doctor or fitness professional for a personalized plan is recommended.

Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.

A 360 kg man from Inner Mongolia, once China’s heaviest person, lost nearly half his weight through bariatric surgery and lifestyle changes in four months, highlighting obesity management challenges. China’s obesity rate has tripled since 2004, with severe obesity (BMI ≥35) causing cascading health risks. Experts stress tiered interventions: behavioral changes, medications (e.g., GLP-1 agonists), and surgery, which requires lifelong monitoring. The global weight loss surgery market, valued at $2.4 billion in 2023, grows as obesity costs economies $2 trillion annually. While technology aids management, lasting success hinges on medical rigor and personal resolve, offering both caution and hope amid rising healthcare burdens.